GSK - Immunome rises 9% as antibody cocktail shows efficacy against Omicron in in-vitro test

Immunome (NASDAQ:IMNM) said in vitro data showed effectiveness of its antibody cocktail against live versions of the SARS-CoV-2 Omicron variant (B.1.1.529) when tested at two external laboratories  (Boston University’s National Emerging Infectious Diseases Laboratories and Washington University). The company said IMM20253 shows a novel mechanism by promoting a proteolytic cleavage of the portion of the spike protein needed for ACE2 binding, thus reducing the ability of the virus to infect host cells. IMM20253 also induced potent non-neutralizing activity via phagocytosis. In a head-to-head test using live virus performed at Boston University, IMM20253/IMM20184 combination neutralized the Omicron variant within 3.5-fold potency compared to S309, the preclinical version of sotrovimab (GlaxoSmithKline (NYSE:GSK)/Vir Biotechnology (NASDAQ:VIR)). In the live virus testing conducted by Boston University and Washington University, each using a different assay, the potency of the IMM20253/IMM20184 combination was measured to be in the range of 27 nM – 100 nM. As a combination, IMM20253

For further details see:

Immunome rises 9% as antibody cocktail shows efficacy against Omicron in in-vitro test